To Be Discontinued Capsule Antiviral
Atazanavir Sulfate Capsule · 464 days since initial FDA posting
Brand: REYATAZ
FDA lists Atazanavir Sulfate Capsule as To Be Discontinued (Bristol Myers Squibb Co.).
No availability text on this FDA row.
Atazanavir Sulfate Capsule: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Atazanavir Sulfate Capsule
- Manufacturer
- Bristol Myers Squibb Co.
- Dosage Form
- Capsule
- Presentation
- Reyataz, Capsule, 200 mg (NDC 0003-3631-12)
- Package NDC
- 0003-3631-12
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Jun 4, 2025
- Last Updated
- Jun 4, 2025
- Therapeutic Category
- Antiviral
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Permanent discontinuation
Nearby, Other Atazanavir Shortage Records
FDA reason on file: Permanent discontinuation. General shortage guidance lives on the tracker hub.